Facebook: World Allergy Organization
Twitter: World Allergy Organization
LinkedIn: World Allergy Organization
Back to Top


Richard F. Lockey, MDFAAAAI

Paul A. Greenberger, MD

Dear Colleagues,

It is good to bring World Allergy Forum back to the vibrant city of New Orleans, for the 37th Symposium in the World Allergy Organization program, Asthma Phenotypes and Heterogeneity of Therapeutic Responses: Personalized Medicine in the 21st Century.

The focus of World Allergy Organization’s activities for 2010-2011 will be allergic co-morbidities, and so it is fitting that our first presentation, from Louis-Philippe Boulet, will look at asthma in patients with obesity. The presentation will guide us about the factors that could lead to an over-diagnosis of asthma in the obese patient. Does obesity lead to asthma, or are there common genetic/environmental influences that predispose to both asthma and obesity? Why is asthma more difficult to control in the obese patient, and what are the optimal management strategies?

Marek Kowalski is a leading authority on aspirin-exacerbated respiratory disease (AERD). We will hear about the pathomechanisms of AERD and new insights into the role of Staphylococcus aureus enterotoxins in the development of underlying chronic airway inflammation in AERD patients. Several AERD phenotype-specific management strategies will be proposed.

Allergic and non-allergic asthma phenotypes will be discussed by Paul O’Byrne, who will consider the finding that even in “non-allergic” asthmatics, associations have been shown between asthma severity and serum IgE levels. Paul will review how monitoring the airway inflammatory response using induced sputum can determine therapy requirements, and will look at the role of monoclonal antibodies and IL-8 receptor antagonists in severe asthma with persisting eosinophilia and neutrophilia.

It promises to be an excellent session!

World Allergy Organization would like to thank the American Academy of Allergy, Asthma and Immunology for hosting today’s symposium, and to acknowledge the unrestricted educational grant from Novartis that supports the World Allergy Forum program.

With best regards,

Richard F. Lockey, MD FAAAAI
World Allergy Organization

Paul A. Greenberger, MD FAAAAI
American Academy of Allergy, Asthma and Immunology

Return to WAF: New Orleans, LA, USA index